Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST

Dermatology Online Journal

Volumn 14, Issue 7, 2008, Pages

  Alexandrescu, Doru T ^a   Dasanu, Constantin A ^b   Farzanmehr, Haleh ^a   Kauffman, C Lisa ^a  

^a Georgetown Dermatology   (United States)

^b Washington Hospital Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; HYDROMORPHONE; IMATINIB; PARACETAMOL; PROMETHAZINE; PROTEIN TYROSINE KINASE; SUNITINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; EDEMA; ENZYME INHIBITION; ERYTHEMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; MACULOPAPULAR RASH; MALE; PATHOGENESIS; PRURITUS; RASH; TUMOR BIOPSY; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; FOLLOW UP; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; RISK ASSESSMENT;

BIOPSY, NEEDLE; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPERPIGMENTATION; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RISK ASSESSMENT;

EID: 48749104326     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003;98:2483-7.
2. Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 2005;14:368-70. MID: 15781678
3. Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol. 2006;45:1471-3.
4. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol. 2004;15:358-9.
5. Robson ME, Glogowski E, Sommer G, Antonescu CR, Nafa K, Maki RG et al. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res. 2004;10:1250-4.
6. Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am. 2006;26:575-92.
7. Isozaki K, Terris B, Belghiti J, Schiffmann S., Hirota S, Vanderwinden JM. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am. J. Pathol. 2000;157:1581-1585.
8. Hirota S, Nishida T, Isozaki ., Taniguchi M, Nishikawa K, Ohashi A, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology. 2002;122:1493-1499.
9. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48:201-6.
10. Brazzelli V, Prestinari F, Barbagallo T, Rona C, Orlandi E, Passamonti F, et al. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J Eur Acad Dermatol Venereol. 2007;21:384-7.
11. Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol. 2006;72:63-4.
12. Singh N, Bakhshi S. Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol. 2007;29:208-9.
13. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491-500.
14. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature. 1998;391:298-301.